Boehringer Asks DC Circ. To Stay Aggrenox Doc Production

By Eric Kroh ( April 12, 2017, 3:39 PM EDT) -- Boehringer Ingelheim Pharmaceuticals Inc. has told the D. C. Circuit it would be irreparably harmed if it were forced to give the Federal Trade Commission documents on a 2008 patent dispute settlement over the drug Aggrenox and has asked the court to stay an order to produce the documents pending appeal. . . .

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login